A detailed history of Farther Finance Advisors, LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 129 shares of NVCR stock, worth $1,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares
129
Previous 92 40.22%
Holding current value
$1,920
Previous $1.43 Million 57.05%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$11.83 - $24.05 $437 - $889
37 Added 40.22%
129 $2.24 Million
Q1 2024

May 13, 2024

BUY
$12.42 - $17.29 $1,092 - $1,521
88 Added 2200.0%
92 $1.43 Million
Q4 2023

Feb 14, 2024

BUY
$11.13 - $15.78 $3,773 - $5,349
339 Added 1994.12%
356 $5.32 Million
Q3 2023

Nov 13, 2023

BUY
$16.15 - $42.35 $209 - $550
13 Added 325.0%
17 $275,000
Q2 2023

May 13, 2024

SELL
$40.29 - $82.51 $14,182 - $29,043
-352 Reduced 98.88%
4 $166,000
Q2 2023

Sep 12, 2023

BUY
$40.29 - $82.51 $161 - $330
4 New
4 $166,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.56B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.